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Abstract 
In the multidisciplinary fields of nanobiology and nanomedicine, single-walled carbon 
nanotubes (SWCNTs) have shown great promises due to their unique morphological, 
physical and chemical properties. However, understanding and suppressing their cellular 
toxicity is a mandatory step before promoting their biomedical applications. In the light 
of flourishing recent literature, we provide here an extensive review on SWCNT cellular 
toxicity and attempt to identify the key parameters to be considered in order to obtain 
SWCNT samples with minimal or no cellular toxicity. 
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 1. Introduction 
Over the past two decades, nanoscience and nanotechnology have been largely impacted 
by the development of carbon-based nanomaterials, such as fullerenes,
1
 nanodiamonds,
2,3
 
graphene,
4
 and carbon nanotubes.
5,6,7
 Carbon nanotubes are attractive due to their 
outstanding electrical,
8
 optical,
9
 mechanical,
10
 thermal properties.
11
 Apart from 
applications in material science, electronics or photonics,
12
 carbon nanotubes also have 
multiple promising applications in biomedicine, serving as biosensors,
13,14
 bioprobes,
15,16
 
drug carriers,
17
 photothermal therapy enhancers
18
 and molecular imaging contrast 
agents.
19
 SWCNTs distinguish themselves from double-walled carbon nanotubes
20
 and 
multi-walled carbon nanotubes
5
 by their single-layer cylindrical sidewall structure, 
provides them more finely tuned physical and chemical properties for applications as 
compared to other carbon structures. Due to their ultra-small diameter, high curvature and 
large surface area (1315 m
2
/g),
21
 they possess highly reactive surfaces
22
 and they can 
interact with biomolecules present in biological systems, like proteins,
23
 DNA
24
 and 
lipids
25
 by weak interactions (e.g. van de Waals, π-stacking, hydrophobic interactions, 
and hydrogen bonds). Reactive surfaces of SWCNTs may offer vast opportunities for 
surface modification and have potential for a variety of applications.
26,27,28
 Conversely, 
direct interactions of SWCNTs with biomolecules might make them deleterious to the 
integrity of cells and organs. In this regard, SWCNTs impact on human health is a rising 
concern within the scientific, industrial, and public communities.
29,30
  
Cell-based experiments are considered the preliminary test for assessing the biological 
safety of nanoparticles before practical applications in biology and medicine. Toxicity of 
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nanoparticles to cells can be evaluated at different levels, ranging from evaluation of the 
plasma membrane integrity to the activation of late intracellular proteolytic cascades and 
DNA fragmentation. Typical tests include the examination of cell growth, cell viability, 
membrane permeability, mitochondrial activity, metabolic activity, oxidative stress, 
immune response, DNA fragmentation, DNA repairing enzymes cleavage, etc. Over the 
past years, a high number of studies have been performed to understand SWCNTs 
cellular toxicity. Many published results are however contradictory and the full 
knowledge concerning nanotube cellular toxicity remains to be established.  
The purpose of this article is to review the current knowledge of SWCNTs cellular 
toxicity, which differs from that of their multiwall counterparts. Previous review 
articles
31
 generally addressed the toxicity of carbon nanotubes regardless of their type 
(single versus multi walled). Our aim is to attempt to identify the critical parameters to be 
taken into account to understand and further minimize SWCNTs cellular toxicity. We 
will consider several aspects of SWCNT sample properties (see Figure 1); among them, 
nanotube synthesis and purification processes will first be discussed. Generally, 
as-produced SWCNT samples are a heterogeneous mixture of nanotubes with impurities 
(mainly metal catalysts and carbon by-products)
32
 and multiple step post-synthesis 
purification procedures are commonly employed to remove such impurities.
33
 In addition, 
SWCNTs do not consist of single molecular species, but instead different chiral angles 
and diameters provide them distinct molecular structures. This can induce specific 
species-related physical properties and (bio)chemical molecular affinities
34,35,36
 which 
could further result in distinct cellular toxicity.
37,38
 Vast improvements of sorting 
techniques have arisen over recent years,
39,40,41
 which could greatly help in the 
Page 3 of 51 Biomaterials Science
understanding of SWCNT cellular toxicity. Furthermore, the strong inter-tube van de 
Waals interactions among pristine SWCNTs can be up to 500 eV/µm,
42,43
 which
 
renders 
pristine nanotubes insoluble in common physiological media.
44
 In order to overcome this 
issue, nanotube encapsulation using amphiphilic molecular moieties (commonly called 
surfactants) is generally used to individualize and solubilize SWCNT in aqueous media.
44
 
Cellular toxicity arising from surfactants rather than nanotubes themselves must also be 
considered. An alternative route for solubilizing SWCNTs consists of functionalizing the 
nanotube surface, thus creating defects on the pristine SWCNT backbone structures.
45,46
 
The contribution of these functional groups on SWCNT cellular toxicity will also be 
discussed in this review. 
 
2. Effect of Synthesis and Impurities  
Several synthesis methods are commonly used for producing SWCNTs, such as chemical 
vapor deposition (CVD),
47
 laser-ablation
48
 and arc-discharge.
49
 Different types of metal 
particles are used as catalysts in the synthesis formulations in order to reduce activation 
energy barriers of the chemical reaction and/or to control nanotube growth orientation. The 
most commonly used metals are Fe, Ni, Co, Mo and Y,
50
 which can therefore be present 
in as-produced nanotube samples. In addition, carbonaceous by-products may also be 
produced, such as nanocrystalline graphite, amorphous carbon, and fullerenes.
51
 As a 
result, as-produced SWCNT samples not only contain nanotubes but also many 
impurities which depend on the synthesis formulations. Impurities can be embedded 
within the inner channels of nanotubes making them difficult to be removed completely 
(see Figure 2a and b).
52
 They might therefore interfere with the pristine properties of 
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SWCNTs and affect the interplay between nanotubes and cells.
53
 Indeed, metal elements 
commonly co-exist with many proteins/enzymes and also participate in various biological 
pathways.
54
 Loading metal particles in cells may cause multiple type of toxicity,
55,56
 such 
as gene silencing and hypoxia signals induction,
57
 ion channel inhibition,
58
 production of 
reactive oxygen species (ROS),
59
 lipid peroxidation
60
 and formation of massive 
mitochondrial and nuclear DNA adducts.
61
 The impact of carbonaceous particles on cell 
integrity might also be significant.
62,63
 In order to reduce the influence of impurities, 
as-produced SWCNTs samples might require thorough purification through various 
chemical and physical treatments,
64
 such as harsh acid washing,
65
 low temperature 
oxidation,
66
 polymer wrapping extraction,
67
 in combination with ultracentrifugation or 
other sorting techniques. Applications of such strategies depend on the SWCNT synthesis 
methods as will be discussed below. 
 
2.1. CVD SWCNTs 
CVD methods allow large-yield production of SWCNTs. CVD commonly produces 
nanotubes through carbon monoxide (CO) disproportionation either under high-pressure 
(HiPco sample)
68
 or with Co-Mo as supported catalysts (CoMoCAT sample).
69
 The former 
technique produces nanotubes with interesting pristine optical properties for biological 
imaging.
70
 The latter allows narrow nanotube chirality distributions. We discuss below the 
impact of the impurities contained in HiPco and CoMoCAT nanotube samples on cellular 
toxicity. 
 
2.1.1. HiPco SWCNTs 
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HiPco samples contain a mixture of nanotubes with different chiralities.
71
 They can also 
contain various metal catalysts used during the synthesis process. A number of studies 
that focused on the interplay between SWCNTs and cells employed unpurified nanotube 
samples, and such impurities played a critical role on cellular toxicity.
72,73,74
 Maria et al. 
studied the impact of HiPco SWCNTs containing 10 wt% Fe on primary human lung 
epithelial cells (A549)
75
, as lung exposure is a primary pathway for human contract with 
nanoparticles. After 24 hours exposure at a dosage of 800 µg/mL, low acute toxicity was 
reported but apparent changes in cell morphology were visualized with transmission 
electron microscopy (TEM). No individual SWCNTs were observed inside cells, while 
an increased number of multi lamellar and vesicular bodies were observed, which was 
hypothesized to arise from a defensive response of lung cells. A549 and human bronchial 
epithelial cells (NHBE) further showed suppressed inflammatory and increased oxidative 
stress responses after exposure to the same nanotubes coated with 
dipalmitoylphosphatidylcholine (DPPC).
76,77
 DPPC coating improves the 
individualization degree of SWCNTs in cell culture medium and led to increased toxicity 
in A549 cells after 48 hours exposure but no had no effect on NHBE cells. This induced 
toxicity can be attributed to impurities (10 wt% in this study) released from DPPC-coated 
nanotubes when incubated with A549 cells.
78
 This observation also indicates that 
SWCNT toxicity depends on the cell type. To also address another important pathway of 
nanoparticle body penetration, Murray et al.
79
 studied the effect of unpurified nanotubes 
on skin cells. Cell oxidative and inflammatory effects were evaluated on EpiDerm-FT 
engineered skin of murine epidermal cells (JB6 P+) through administration of unpurified 
HiPco SWCNTs containing 30 wt% Fe and their purified counterparts containing only 
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0.23 wt% Fe.
79
 A significant induction of activator protein 1 (a transcription factor 
regulating gene expression in responses to various stimulus)
80
 was observed upon 
exposing unpurified HiPco SWCNTs to JB6 P+ cells, but no activation was observed 
using purified HiPco nanotubes. Further topical exposure of unpurified HiPco nanotubes 
to immune-competent hairless SKH-1 mice after 5 days at daily dosage of 40 µg/mouse 
led to increased oxidative stress, depletion of glutathione, oxidation of protein thiols and 
carbonyls, and elevated myeloperoxidase activity, thereby resulting in an increase of 
dermal cell numbers and thickening of the animal skin. In an attempt to obtain 
bio-compatible nanotube samples by coating them with biomolecules, Patrick et al.
81
 
used bovine serum albumin (BSA), a bioactive blood protein widely used as blocking 
reagents for reducing non-specific bindings, as an encapsulating macro-molecule. The 
authors reported the cellular uptake of HiPco SWCNTs (containing 5 wt% carbonaceous 
and 0.3 wt% metallic impurities) by murine macrophage-like cells (J774A.1) and 
NIH-3T3 cells.
81
 BSA-coated SWCNTs reduced cell proliferation in a dose-dependent 
manner and increased cell sizes at a dosage level of 30 µg/mL, most likely due to 
increased amounts of impurities. More recently, Holt and coworkers reported that 
BSA-coated SWCNTs were taken up by human mesenchymal stem cells and HeLa cells 
without apparent acute effects.
82
 
Altogether the investigations mentioned above suggest that the impurity content in HiPco 
nanotube samples and the role of encapsulating agents are important parameters in 
cellular toxicity. Sample purification might be employed to reduce impurities and 
therefore toxicity. The impact of encapsulating compounds will be detailed in section 
3.1.2.  
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 2.1.2. CoMoCAT SWCNTs 
CoMoCAT nanotube samples have a narrow chirality distribution, generally enriched in 
(6.5) nanotubes.
69
 CoMoCAT formulation involves the use of Co-Mo bi-metallic 
catalysts supported on a SiO2 substrate.
83
 Purification processes are usually achieved by 
low temperature oxidation to remove amorphous carbon, hydrofluoric acid washing to 
remove the SiO2 substrate, and hydrochloric acid (HCl) treatment to remove Co-Mo 
bi-metallic catalysts that mostly attach to nanotube ends. Yehia et al. investigated the 
cellular toxicity of CoMoCAT SWCNTs (thoroughly purified sample containing 6.64 
ppm Co and 1.55 ppm Mo; dosage of 50 µg/mL; 100-400 nm in length) in HeLa cells.
84
 
Nanotubes were suspended in Dulbecco’s modified eagle medium (DMEM) containing 
fetal bovine serum (FBS) 5 v/v% (DM-SWCNTs). MitoRox
TM
 Red assay suggested that 
superoxide levels in mitochondria were similar for both incubations, with and without 
nanotubes. HeLa cell morphology and proliferation showed no apparent change after 
exposure to DM-SWCNTs compared with unexposed cells over 4 days. This 
investigation indicated that DM-SWCNTs were not inherently toxic because the 
impurities were efficiently removed. CoMoCAT samples with low number of impurities 
(Co-Mo 1.8 wt%, dosage of 10 µg/mL) similarly showed low cellular toxicity to E. coli 
K12 cells after 1 hour exposure.
85
 
The cellular toxicity of CoMoCAT coated with biomolecules was investigated by Bertulli 
et al., assessing the long-term effects of BSA-coated CoMoCAT SWCNTs, purified by 
low temperature oxidation and acid treatments 200-300 nm in length, dosage of 8 µg/mL 
on macrophages.
86
 No significant difference in cell proliferation and viability was 
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observed between cells exposed to reference and BSA-coated SWCNTs during 65 hours 
(corresponding to three cell division cycles). This result supports the observations made 
on HiPCO nanotubes suspended in BSA where toxicity was primarily attributed to 
sample impurities.
81
 Ge and coworkers further examined the cellular toxicity of SWCNTs 
(Co as catalysts) coated by different blood proteins, including bovine fibrinogen (BFG), 
gamma globulin, transferrin, and BSA in human acute monocytic leukemia (THP-1) and 
human umbilical vein endothelial cells (HUVECs).
87
 Interestingly, BFG-coated SWCNTs 
showed the lowest toxicity, which might be due to the tighter binding of BFG proteins to 
nanotubes preventing direct contacts of the nanotube backbone with cellular components. 
These results suggest that blood proteins can be promising candidates for coating 
SWCNTs by reducing interactions between nanotubes and cellular components. They 
might also suggest that bare nanotubes can adsorb proteins in the bloodstream, although 
the fate of nanotubes in the bloodstream is not yet understood. 
 
2.1.3. Arc-Discharge SWCNTs 
The synthesis of SWCNTs by arc-discharge utilizes a composite anode, usually placed in 
hydrogen or argon atmosphere.
88
 The anode is made of graphite and a metal, such as Ni, 
Fe, Co, Pd, Ag, Pt, etc; or the mixture of Co, Fe, and Ni with other elements. 
Arc-discharge SWCNTs have diameters of 1.4-2 nm and lengths of several µm. The 
reaction products include many metal catalyst residents and unexpected products such as 
MWCNTs and fullerenes.
49
 Aditya et al. reported the influence of arc-discharge 
SWCNTs on 3T3 mouse fibroblasts.
89
 As-produced (AP-SWCNT, Ni 0.73 wt%, Y 0.38 
wt%), purified (Pur-SWCNT, Ni 0.07 wt%, Ni 0.04 wt%), and glucosamine-modified 
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(GA-SWCNT, Ni 0.09 wt%, Y 0.03 wt%) arc-discharged nanotubes were incubated with 
3T3 mouse fibroblasts for 3 days at concentrations up to 0.1 wt%. It was found that 3T3 
cell viability and metabolic activity strongly depend on nanotube preparation, 
purification, and concentration. AP-SWCNTs showed the largest cellular toxicity, 
Pur-SWCNTs showed a mild toxicity while GA-SWCNTs showed the lowest cellular 
toxicity. These results demonstrated again that the impurity content of carbon nanotube 
samples significantly affects cellular toxicity for HiPco and CoMoCAT nanotubes. 
 
2.1.4. Laser-Ablation SWCNTs 
Laser-ablation formulation produces SWCNT samples containing a high content of carbon 
arc-materials and metal catalysts that require to be removed by extensive purification.
90
 
Warheit et al. investigated the cellular toxicity of laser-ablation SWCNTs to pulmonary 
cells. SWCNT samples containing 30-40 wt% amorphous carbon and 5 wt% Ni and Co
91
 
were directly dispersed in phosphate-buffered saline (PBS) containing 1 wt% Tween80 
and used in cells experiments without further purification. No significant change of cell 
proliferation was found compared to control samples following 24 hours cell exposure at 
a dosage of 5 µg/mL. SWCNTs samples used in this study were however rarely found as 
individualized nanotubes, but rather in agglomerated ropes. The effects of nanotube 
aggregation on cellular toxicity will be discussed in Section 4.2.  
Pulskamp et al. studied the responses of lung macrophages (NR8383) and A549 cells to 
the exposure of laser-ablation SWCNTs purified by acid treatment containing traces of 
Ni/Co catalysts.
92
 After 24 hours nanotube exposure to cells at a dosage of 100 µg/mL, 
no acute toxicity was reported on cell viability. In contrast, the use of unpurified 
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commercial SWCNTs (CVD, Nanostructured & Amorphous Materials Inc., Los Alamos, 
USA) indicated a dose- and time-dependent increase of intracellular reactive oxygen 
species and a decrease of mitochondrial membrane potential in both NR8383 and A549 
cell lines, revealing the impact of impurities in laser-ablation nanotube sample on cellular 
toxicity.  
 
2.1.5. Comparison between SWCNT synthesis methods and toxicity mechanism 
In order to gain insight into the cellular toxicity of different SWCNT formulations, 
Chowdhury et al. tested on bacteria the toxicity of SWCNTs produced by HiPco, 
CoMoCAT, and arc-discharge methods.
85
 SWCNTs were dispersed in water containing 2 
wt% F108 copolymer, and their toxicity was determined by live/dead baclight bacterial 
viability tests. This study suggested that HiPco (Fe 6.52 wt%) nanotubes have greater 
impact on cell viability as compared to CoMoCAT (Co-Mo 1.80 wt%) and arc-discharge 
nanotubes (Y-Ni 0.21 wt%) at a same dosage of 10 µg/mL after 1 hour exposure. 
The observations mentioned above suggest that regardless of the synthesis method, metal 
catalysts/impurities embedded in SWCNTs samples have a deep impact on cellular 
toxicity. A possible molecular mechanism of cytotoxicity induced by cell exposure to 
carbon nanotubes and leached metallic particles has recently been proposed.
72
 The 
cellular toxicity of SWCNTs was suggested to be mediated by ROS and the related 
disorder of intracellular metabolic pathways.
93,94
  
As a first conclusion, the use of SWCNTs samples containing low metal impurities is 
important to obtain reduced cellular toxicity. The control of SWCNTs’ cellular toxicity 
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primarily requires a control on nanotube sample impurity contents through synthesis and 
purification processes.  
 
3. Effect of nanotube length and aggregation 
The impact of nanoparticles on living cells depends on several parameters such as their 
physical size, hydrodynamic volume, aggregation states, colloidal stability in 
physiological environment etc.
95
 It is well known that SWCNTs in colloidal suspensions 
are relatively heterogeneous in length, and contain both individualized nanotubes and 
bundles. In this section, we summarize reported effects of nanotube lengths and 
aggregation states on cellular toxicity. 
 
3.1. Length 
SWCNTs have very large aspect-ratios (length-to-diameter), which complicates the 
understanding of size effects involved in cellular toxicity. The lengths of SWCNTs are 
believed to play essential roles in nanotubes internalization pathways,
96,97
 cellular 
responses
98
 and subcellular distribution.
99
 Kang et al. reported the effect of SWCNT 
lengths (chitosan-coated nanotubes, dosage of 50 µg/mL) on cell internalization 
pathways
99
 and suggested that 100-200 nm long nanotubes are internalized in cells 
through clathrin-coated vesicles and the caveolin-dependent pathways. In contrast, 50 nm 
short nanotubes could directly enter cells through an energy-independent pathway 
involving insertion and diffusion across the cell membrane. After internalization, 100-200 
nm long nanotubes were found to localize mainly in the cytoplasm, while 50-100 nm 
short nanotubes were found to distribute closer to cell nucleus. Sato and coworkers’ 
Page 12 of 51Biomaterials Science
investigations indicated that cell toxicity caused by exposure to 220 nm long nanotubes 
was weaker than the toxicity induced by 825 nm long nanotubes.
100
 Donkor et al. 
reported that short SWCNTs (coated with 6-arm branched PEG) with length below 35 nm 
could efficiently deliver 4700 bp plasmid DNA molecules into HeLa cells in 24 hours to 
obtain transfected cells.
101
 Moreover, short nanotubes were reported to be less hazardous 
to DNA than their longer countparts.
102
 A very recent study suggested that short 
SWCNTs (1.5 nm in diameter, 10 nm in length, coated by 
1,2-dioleoyl-sn-glycerol-3-phosphocholine (DOPC) at a concentration of 10 mg/mL) 
were able to spontaneously insert into the lipid bilayer of cell membranes. This leads to 
the formation of artificial ‘molecule channels’ capable of translocating water, ions, 
protons and DNA molecules.
103
 From a bio-safety point of view, these results imply that 
extremely short DOPC-SWCNT complexes may interfere with the structure and function 
of cell membranes.  
 
3.2. Aggregation 
The aggregation state of SWCNTs is also an important parameter for minimizing their 
cellular toxicity.
104
 SWCNTs can form large aggregates (micrometers in diameter) in cell 
culture medium or inside the cell body.
105
 Umemoto and coworkers
106
 reported that 
nanotube aggregates induced relocation of cell clathrin complexes in mast cells 
(RBL2H3) just after 10 min of exposure, and reduced the total clathrin level after 1 hour 
(NanoLabs, Detroit, USA. CVD, 5 wt% Fe impurities, 10 to 100 µg/mL). Further studies 
revealed striking membrane perturbations and rearrangements around nanotube 
aggregation zones in mast cells as a consequence of a strong disruption of the cortical 
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actin cytoskeleton. Characterizations performed at the molecular level indicated that 
nanotube aggregations induced biphasic calcium response and phosphorylation of 
post-receptor kinases related to FCER1 receptors (a high affinity receptor for the Fc 
region of the immunoglobulin E). Altogether, these observations suggest that nanotube 
aggregates activate pro-inflammatory responses of mast cells. Peter et al.
107
 compared the 
cellular toxicity of well-dispersed SWCNTs (arc-discharged nanotubes with Ni and Y 
catalyst, polyoxyethylene sorbitan monooleate (PS80)-coated nanotubes, dosage of 50 
µg/mL) as well as puriﬁed rope-like aggregated nanotubes (HCl treatment, 15 minute) 
and soot-like nanotubes-pellet fractions (centrifugation pellet) with commercial asbestos 
as a reference in human MSTO-211H cells. Cell morphology analyses suggested that 
well-suspended SWCNTs were less toxic than asbestos and that rope-like nanotube 
aggregates induced more pronounced toxicity than asbestos ﬁbers at identical 
concentrations. Raja et al.
105
 examined the impact of SWCNTs (0.1 mg/mL HiPco, 
sonicated in a 3:1 (v/v) mixture of H2SO4 and HNO3) on rat aortic smooth muscle cells 
after 3.5 days of incubation. Unfiltered samples containing nanotube aggregates 
significantly decreased cell-growth rates compared to filtered ones.  
From these studies, it clearly appears that aggregation of SWCNTs should be avoided and 
that nanotube individualization is a key parameter to minimize cellular toxicity. 
 
4. Surface Modification of SWCNTs 
As already suggested above, cellular toxicity of SWCNTs can also be influenced by 
nanotube surface exposure to cellular environment.
96,108,109
 In this section, we now 
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discuss the impact of diverse surface modification strategies (see Figure 3) used in 
biological studies to introduce nanotubes in biological samples. 
Pristine SWCNTs are insoluble in water due to their hydrophobic surfaces and direct 
exposure of pristine nanotubes to biological systems might lead to interactions with 
various biomolecules. For examples, in the bloodstream, many proteins and biochemical 
species can adsorb onto nanotubes in an unspecific way.
110
 In this sense, it is important to 
shield or modify the surface of pristine SWCNTs to make them inert to chemical and 
biological components of the cells. The surface of SWCNTs can also contain various 
defects and chemical groups
111
 that might play a role in nanotube interactions with 
biological molecules. Conversely, certain covalently doped SWCNTs have been shown to 
provide new optical or chemical properties promising for bioimaging or sensing 
applications,
112,113,114
 such that controlling nanotube surface exposure to their 
bio-environments might also be promising to retain their properties.  
Encapsulation of nanotubes by hydrophilic moieties and chemical grafting of solubilizing 
agents on nanotube surfaces are the two commonly used approaches preparing nanotube 
aqueous solutions with solubility up to concentrations in the order of g/mL.
115
 For 
bio-applications, many small biomolecules, polymers and surfactants have been used. 
Among them, poly(ethylene glycol) (PEG) arose as the most widely used biocompatible 
moiety for modifying nanoparticle surfaces (termed as PEGylation) due to its proven 
biological inertness and hydrophilic properties.
116
 PEG chains are relatively flexible in 
physiological environments and are able to undergo long-time circulation in blood due to 
the strong resistance against non-specific protein absorption. It was also suggested that 
PEG modified nanoparticles are promising for penetrating various biophysical barriers, 
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such as the reticulo-endothelial system and blood-brain barriers.
117
 This is essential for 
increasing the accessibility of nanoparticles and the specificity for in vivo targeting 
applications.  
We summarize below the cellular toxicity of SWCNTs coated by either covalent or 
non-covalent approaches. We outline several widely employed surface coatings and put a 
particular focus on PEG-based strategies due to their wide applicability in biomedical 
usages. 
 
4.1. Covalent Modification 
Chemical modification of SWCNTs sidewalls is a widely used approach for solubilizing 
nanotubes in aqueous media. It is usually achieved by grafting functional moieties onto 
initially oxidized SWCNT sidewalls (see Figure 3).
118,119
 Oxidation of nanotubes is 
performed using H2SO4 and/or HNO3 to create carboxylic groups. Importantly, oxidized 
SWCNTs used without further coating were reported to induce multiple toxic effects to 
cells. For example, Singh et al. reported cell chirality loss, centrosome disintegration, 
tubulin network disorganization, adhesion complex maturation and decrease of migration 
ability during multicellular alignment or migration after cellular exposure to oxidized 
SWCNTs.
120
 Such oxidized SWCNTs were also reported to induce multipolar spindle 
and abnormal mitosis.
121
 Luanpipong et al. reported that direct chronic exposure of 
oxidized SWCNTs to lung epithelial cells would induce the production of cancer stem 
cells with malignant properties
122
 and that these cells could become aggressive and 
develop tumors. These nanotubes might thus be more toxic than pristine unpurified 
nanotubes, which reflects the impact of surface defects and chemical groups introduced 
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by oxidation.
123
 Therefore, oxidized SWCNTs without further surface modification 
should be used with caution for both in vitro and in vivo applications.  
In this context, it was shown that grafting anti-fouling polymers onto nanotube backbones 
provides an efficient approach for minimizing SWCNTs direct interactions with cellular 
components. For instance, PEG-modified SWCNTs are commonly used and are usually 
produced by amidation reaction of -COOH groups of oxidized nanotube with -NH2 
groups of PEG. PEG-modified SWCNTs produced with this approach stabilize nanotubes 
as individual and/or small bundles in colloidal suspensions and are stable in high salt and 
serum containing environment.
124
 Zhang et al. investigated the toxic effects of linear 
PEG-modified SWCNTs and compared it to non-modified SWCNTs on PC12 cells.
125
 
Using high concentration of 100 µg/mL during 24 hours exposure, linear PEG-modified 
SWCNTs were found to be much less toxic than non-modified counterparts (as indicated 
by water soluble tetrazolium reduction assay). Similarly, based on lactate dehydrogenase 
release assays, it was found that linear PEG-modified SWCNTs caused less cell 
membrane damage than non-modified nanotubes. The morphology of these cells was also 
differentially affected, as cells treated with oxidized SWCNTs had an elongated shape 
while linear PEG-modified nanotubes did not induce such morphological changes. 
Dose-dependent ROS and significant glutathione depletion were found after 24 hours 
administration of both materials. However, linear PEG-modified SWCNTs showed 
considerably less effect to oxidative stress related genes in PC12 cells compared to 
non-modified nanotubes. Once again, these findings indicate that the cellular toxicity 
mechanism of nanotubes is associated with oxidative stress. Importantly, these results 
suggest that PEG modification reduces oxygen species generation induced by nanotube 
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administration. 
In order to study the effect of PEG structures on nanotube cellular toxicity, Heister et al. 
compared HeLa cell viability after exposure to branched PEG-modified and 
non-modified SWCNTs.
126
 Unlike non-modified SWCNTs which formed 
clusters/precipitates in cell culture media, branched PEG-modified nanotubes (10 kDa) 
were more stable and disperse. In addition cell viability stayed at 100 % over the whole 
dosage range from 0.01 to 100 µg/mL after 4 days of incubation. This observation 
suggests that branched PEG-modified SWCNTs are able to isolate nanotube surfaces 
more efficiently from exposure to cellular components compared to linear PEG chains.  
Covalent PEG modifications can also be achieved through grafting PEG molecules onto 
-NH2 groups. These groups are introduced on SWCNT surfaces by adding pyrrolidine 
rings to nanotubes via 1,3 dipolar cycloaddition reaction in azomethine ylides with 
subsequent thermal condensation in α-amino acids and aldehydes.
115
 These PEG 
modified nanotubes are stable in various colloidal suspensions. They do not induce any 
complement reaction due to high structural stability.
127
 Indeed, it was shown that the PEG 
chains on SWCNTs are unable to interact with the natural anti-PEG factor that is 
involved in the complement reaction induced by PEG molecules in biological systems.  
Altogether, these studies indicate that PEG covalent grafting strategies dramatically 
reduce the cellular toxicity of oxidized SWCNTs. Branched PEG-modified SWCNTs 
appear to be more biocompatible than linear PEG-modified counterparts due to compact 
binding and large coverage of nanotubes, which limits the nanotube backbone exposure 
to cellular components. Yet, the effects of PEG density, length and branch degree are yet 
to be systematically investigated to fully understand their impact on cellular responses 
Page 18 of 51Biomaterials Science
and toxicity. 
 
4.2. Non-covalent encapsulation 
The covalent modification of nanotube surfaces discussed above induces sp
3
 
hybridization bonds through the introduction of chemical groups. These modifications 
can have important detrimental implications on the mechanical, physical or chemical 
properties of nanotubes. For instance, heavy covalent nanotube functionalization 
generally suppresses the intrinsic near-infrared (NIR) photoluminescence properties of 
nanotubes
128
 whereas many bio-applications of SWCNTs are based on these 
properties.
129
 For such applications, non-covalent-based nanotube solubilization using 
biological compatible amphiphilic materials (soft polymers and biomolecules) is a widely 
used strategy (see Figure 3).
70
  
In general, cationic, anionic or nonionic charged surface coating can be used to 
encapsulate SWCNTs and to control the outer charge of the coated nanotubes. As the 
plasma membrane is negatively charged, the surface charge of encapsulated SWCNTs is 
a key parameter for controlling nanotube-cell membrane interactions, nanotube 
internalization pathways and intracellular fate. Usually, cationic nanoparticles interact 
more strongly with the cell membrane and therefore show higher uptake efficiency 
compared to anionic and neutral nanoparticles.
130
 Negatively charged nanoparticles are 
also known to be taken up efficiently by pinocytosis or following membrane 
diffusion.
131,132,133
 Keeping nanotube surfaces neutrally charged thus appears to be key 
for reducing nanotubes non-specific binding to cell membranes and serum proteins. In 
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addition, nanoparticle hydrophobicity should also be controlled as it plays an important 
role in cellular uptake processes and subcellular fate.
134,135
  
More specifically, ionic detergents (such as sodium dodecyl benzene sulphonate, sodium 
dodecyl sulfate, cetyltrimethylammonium bromide, sodium cholate or sodium 
deoxycholate) are frequently used as excellent suspension agents of SWCNTs.
136,137
 
However, because of the well-known cytotoxicity of these ionic surfactants, they are not 
ideal for SWCNT biological applications. On the other hand, nonionic surfactants (e.g. 
pluronic) can also disperse SWCNTs and be used in cellular applications.
138,139
 Low 
cellular toxicity of pluronic F108-coated nanotubes was previously reported,
140
 however, 
recent developments illustrate that serum proteins in the bloodstream can replace F108 
molecules and stick to SWCNT surfaces in physiological environments, which could 
restrict the performance of this surfactant.
141
 Interestingly, collagen has also been used to 
suspend SWCNTs with no apparent effects on viability of bovine chondrocytes at a high 
dosage (15 µg/mL) after 15 days exposure.
142
  
Phospholipid-polyethylene glycol (PL-PEG), deserves a particular focus since it has 
become a widely used non-covalent suspension agent for bio-applications of SWCNTs 
both in vitro and in vivo.
70,143,144,145,146
 The hydrophobic PL chains attach to the surface of 
nanotubes, with the hydrophilic PEG chains increasing the solubility and stability of 
nanotubes in high salts and serum containing environments. It is worth noting that 5 kDa 
linear PL-PEG-coated SWCNTs have been reported to trigger complement system 
reactions in vitro via the lection pathway, but neither acute nor chronic toxicity was 
observed for these materials both for in vitro and in vivo tests as a consequence of 
complement activation.
147
 It was similarly found that PL-PEG incorporated into 
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liposomes activates the complement system in human serum through an alternative 
pathway via interaction with naturally existent anti-PEG antibodies.
148
 We note that 
BSA-, RNA-, glycolipid-, and non-coated SWCNTs were also reported to trigger 
complement activation.
127
 However, recent studies suggested that complement activation 
reaction could be avoided by slightly modifying the chemical structure of the surfactants. 
For example, complement activation by PL-PEG could be avoided by mutating anionic 
phosphate site into a methylated site
147
 since it activation arises from the anionic 
phosphate site in the PL-PEG structure. 
DNA molecules represent another class of biomolecules commonly used to solubilize 
SWCNTs in the context of potential biomedical applications.
24
 DNA is flexible 
biopolymer capable of adjusting its molecular geometry to wrap around the SWCNT 
outside walls by forming a helical structure.
24,36
 This is achieved by non-covalent 
interactions (mainly π-stacking interactions) between SWCNT backbones and the 
aromatic nucleotides along the DNA perpendicular axis. This compact DNA wrapping 
can be SWCNT chirality selective depending on DNA sequences.
149
 Importantly, DNA 
being naturally biocompatible, DNA-coated SWCNTs can be expected to show little 
cytotoxicity. Dong et al. demonstrated that low doses (GT)15-coated SWCNTs (0.8 
µg/mL) have no detectable impact on human astrocytoma cell morphology, proliferation, 
or viability after 24 hours exposure, as opposed to nanotubes coated by SDBS or SDS.
150
 
Accordingly, Jin et al. reported no apparent cytotoxicity in live NIH 3T3 cells exposed 
for several hours to (GT)15-coated SWCNTs at the same dose. Such low SWCNTs doses 
are typically used in live cell experiment aiming at studying nanotube endocytosis and 
intracellular trafficking at the single nanotube level.
151,96
 Indeed, DNA-coated nanotubes 
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are usually found to strongly interact with cells and thus get internalized. The absence of 
cytotoxicity at higher doses of DNA-coated SWCNTs has yet to be determined. In 
addition, several studies have suggested that the adsorption of biomolecules present in 
cellular serums on DNA-coated SWCNTs and the nanotube cellular uptake might depend 
on DNA sequence, nanotube chirality
152
 and length.
108
 Additional studies are required to 
fully understand the nature and stability of DNA-nanotube interactions and the interplay 
of DNA-coated SWCNTs with biological systems.  
Interestingly, several studies have also explored peptide-PEG
153
 and DNA-PEG
14
 
conjugations as new SWCNTs coatings. The impact of these surfactant-nanotube 
complexes on cellular toxicity remains to be investigated. 
 
4.3. Surface coverage density 
The density of chemical functionalities on the sidewall of SWCNTs significantly affects 
the surface properties of the nanotubes and their fate in biological systems. For instance, 
Sayes et al. examined the cellular toxicity of HiPco SWCNTs in human dermal 
fibroblasts (HDF) varying the density of phenyl-SO3X functional groups covalently 
grafted on the nanotubes (purified by acid treatment, containing 1 wt% impurities).
154
 
The average density of phenyl-SO3X groups was controlled by the carbon/phenyl-SO3X 
ratio (18, 41, and 80). This study indicated that SWCNTs were less cytotoxic as the 
degree of sidewall functional density increased.  
Similar to covalently modified SWCNTs, non-covalently suspended carbon nanotubes 
showed improved solubility
70
 and reduced toxicity with an increasing coverage of coating 
molecules. For examples, Liu et al. studied the effect of PEG length and nanotube surface 
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coverage density on the nanotube circulating lifetime and accumulation in live mice 
skin.
155
 It was found that poly(maleic anhydride-aIt-1octadecene)-poly(ethylene glycol) 
(C18PMH-PEG) coated SWCNTs showed the longest circulating lifetime (up to 20 
hours) due to their compactness upon nanotube binding and large surface coverage. The 
same group reported that branched PEG chains could also be used. The extension of 
hydrophilic star-like PEG chains in biological surrounding allowed imaging the 
nanotubes for up to 10 hours in mice.  
Another study addressed the impact of PEG length and nanotube surface coverage 
density by monitoring protein adsorption on SWCNTs using either covalently grafted or 
non-covalently attached PEG moieties.
156
 It was shown that PEG conformational 
transition from mushroom to brush state was key for reducing non-specific protein 
absorption,
156
 which may help to reduce nanotube toxicity and prolong circulation 
lifetime in bloodstream.
157
 
For both covalent and non-covalent surface coverage, increasing PEG density and 
branched degree not only improved the solubility of SWCNTs in biological fluids, but 
also made nanotubes less toxic by reducing unspecific interactions with biological 
components, especially proteins.
126
 
 
5. Effect of SWCNT-Protein Corona 
In biological fluids, binding of biomolecules onto nanoparticle surfaces might lead to the 
formation of supramolecular complexes, usually called the nanoparticle-biomolecule 
corona.
158
 Knowledge of the dynamic rates, affinities, and stoichoimetry of 
nanoparticle-protein association/dissociation is fundamental for understanding the 
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properties of these complexes.
159
 In particular, these coronae directly impact the fate of 
nanoparticles in biological systems, in terms of pathophysiology,
160
 biological 
performance,
161
 and toxicity.
159,161
 In this section, we focus on the impact of 
PEG-modified SWCNT-protein coronae on cellular toxicity. Indeed, PEG chains are used 
to minimize the formation of the protein corona, thus allowing a better control on 
nanoparticle fate in many applications.
162,163
 However, PEG molecules do not completely 
prevent dynamic protein binding, especially when the PEG coverage of nanoparticle 
surface is not total.
164
 In addition, and as mentioned above, covalent and non-covalent 
approach can be used to coat SWCNT surfaces. Sacchetti et al. systematically 
investigated the protein corona properties of arc discharge SWCNTs surface coated with 
2kDa PEG chains through either covalent or non-covalent approaches (see Figure 4a and 
b).
157
 In this study, non-uniform coating was observed on the sidewall of non-covalent 
PEG-coated SWCNTs (terms as cPEG-SWCNTs) leaving open areas that extend up to 
tens of nanometers that could directly expose the nanotube surface to biological 
environments. In contrast, covalent PEG-functionalized SWCNTs (fPEG-SWCNTs) 
displayed a denser and more uniform PEG layer on nanotube surfaces. After removing 
unbound PEG, cPEG2-SWCNTs and fPEG2-SWCNTs showed respectively a PEG 
density of 0.1 mmol (PEG average height 1 nm, mushroom conformation) and 0.4 mmol 
(PEG average height 7 nm, mushroom-brush transition conformation) per gram of 
nanotubes. Analysis of human plasma proteins adsorbed on nanotubes were studied by 
mapping with 1D SDS-polyacrylamide gel electrophoresis combined with a mass 
spectrometry after incubating plasma with nanotubes. The results revealed clear 
differences in the composition of PEG2k-SWCNT coronae as a function of nanotube 
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surface properties and proteins properties: fPEG2-SWCNTs mainly adsorbed coagulation 
proteins whereas cPEG2-SWCNTs mainly adsorbed immunoglobulin proteins (see 
Figure 4c and d). In addition, some plasma proteins were selectively enriched or 
depleted depending on the type of PEG coating used. The influence of PEG conformation 
was subsequently tested by in vivo distribution studies using PEG2k-SWCNTs
157
 
confirming that surface modification (covalent vs non-covalent), size, and PEG 
conformation together influence the composition and dynamics of nanotube-protein 
corona.
165
  
 
6. Conclusions and Challenges 
In this review, we presented recent advances in the understanding of SWCNTs cellular 
toxicity. We showed that SWCNTs cellular toxicity is related to many factors, such as 
nanotube synthesis, impurity content, surface modification, nanotube length, nanotube 
aggregation state and protein corona formation. In addition, the reliability and accuracy 
of the methods used for assessing the toxicity of the nanotubes may need to be 
considered.
166,167
 Interdisciplinary knowledge on nano-bio interfaces in materials science, 
physics, chemistry, biology, and medical engineering, is thus required to understand 
SWCNT toxicity and move towards better control of nanotube impact on biological 
specimens.  
We can attempt to draw a general strategy (although not a complete one) for minimizing 
SWCNT cellular toxicity (Figure 5). First, regardless of nanotube synthesis method, 
metallic impurities and carbon byproducts present in SWCNT samples need to be entirely 
removed by using dedicated purification processes. The cellular toxicity is also strongly 
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associated with SWCNT properties (e.g. length, aggregation, and stability) in various 
suspensions. These need to be rationally controlled during preparation. Second, in order 
to reduce non-specific absorption of biomolecules, it is necessary to incorporate robust 
anti-fouling coatings on nanotube surfaces in order to isolate the nanotube backbone from 
biological environments and further minimize the formation of nanotube-protein corona. 
It is key to achieve a full coverage of nanotube surfaces by incorporating a dense, 
compact, and biocompatible coating. Many natural biomolecules and synthetic polymers 
can be good candidates for nanotube coating but PEG surface modification (PEGylation) 
currently seems to provide the best option. PEG indeed gathers a combination of 
excellent properties: water solubility, low absorption to proteins, low toxicity, and long 
lifetime circulation. Third, the administration conditions (incubation approach, time, 
concentration etc.) need to be rationally chosen. 
In this context, several challenges still remain to fully understand and minimize SWCNT 
cellular toxicity. A major challenge is certainly to produce high-purity and 
chirality-controlled nanotube samples.
168,169,170
 Although PEG-nanotube complexes are 
widely used, new biocompatible surface coatings with ultra-low nonspecific protein 
absorption must be prepared when the use of PEG should be avoided.
171,172
  
More generally, one should emphasize that further studies on SWCNT clearance, 
removal, and degradation in living systems will be necessary in order to fully understand 
their fate.
173,174
 The dosage and hydrodynamic size of nanotubes after binding plasma 
proteins need to be correctly monitored.
175,176,177
 In addition there is no standard tool for 
assessing SWCNT cellular toxicity.
178
 In many experiments, the chemical reagents used 
for assessing toxicity directly interact with nanotubes in the absence of cells and can lead 
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to false results and misunderstanding
179
 which hinder fair comparison between reports. 
Finally, investigations at the molecular and genetic level will certainly be needed. This 
would allow the molecular mechanisms of nanotube induced genetic toxicity, such as 
DNA damage,
180,181
 multiple poles in cell mitosis,
121
 and interruption to chromosome
182
 
to be uncovered.  
In spite of clear challenges, SWCNT-based biomedical materials and devices have shown 
spectacular progresses in recent years and as such they hold great promises for 
innovations in biology and medicine.
183
  
 
Acknowledgments 
This work was supported by CNRS, Agence Nationale de la Recherche 
(ANR-RPIB-004-03), Conseil Régional d'Aquitaine (2011-1603009), the 
France-BioImaging national infrastructure (ANR-10-INBS-04-01) and IdEx Bordeaux 
(ANR-10-IDEX-03-02). JAV acknowledges Marie Curie Individual Fellowship 326442 
funding. The authors gratefully acknowledge Lisa-Maria Needham for her constructive 
comments on the manuscript. 
 
Page 27 of 51 Biomaterials Science
Figure captions 
 
Figure 1. Key parameters associated to SWCNT cellular toxicity. 
Figure 2. Typical electron microscopy micrographs of Ni-containing SWCNT samples 
before (a), and after purification (b). Reproduced from ref 55 with permission from John 
Wiley & Sons.  
Figure 3. Surface modification of SWCNTs for bio-applications. Covalent approaches 
frequently consist in grafting moieties from pyrrolidine rings or carboxylic groups while 
noncovalent approaches are based on SWCNTs encapsulation using amphiphilic 
molecules. Examples of PEG (e.g. PL-PEG), pluronic (e.g. F108), proteins (e.g. BSA) 
and single-strand DNA are pictured. 
Figure 4. PEG2k-SWCNTs interactions with human plasma proteins. (a) 
PEG(2k)-coated SWCNTs (cPEG2-SWCNTs). (b) and PEG(2k)-functionalized SWCNTs 
(fPEG2-SWCNTs). Different linear 2 kDa molecular weight PEG chains having amino 
groups, methylgroups, or NIR-emitting dyes (Seta750) at their distal ends were used to 
investigated the protein corona. (c, d) Relative abundance of human plasma proteins 
adsorbed onto PEG2-SWCNTs. Samples of PEG2-SWCNTs were incubated with human 
plasma proteins at 37 ºC and free plasma proteins were separated on 1D SDS-PAGE (c); 
the donor-averaged relative abundances for these groups were calculated for 
PEG2k-SWCNTs and free plasma (d). Reproduced from ref 156 with permission from 
the American Chemical Society.  
Figure 5. General strategy for minimizing SWCNT cellular toxicity. 
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